Evolution of the Average Target: Aligos Therapeutics, Inc.

Evolution of the Average Target - Aligos Therapeutics, Inc.

Evolution of the Target Price: Aligos Therapeutics, Inc.

Evolution of the Target Price - Aligos Therapeutics, Inc.

Changes in Analyst Recommendations: Aligos Therapeutics, Inc.

fa8e905535e097cac.EPb8jMAlhHLELxqvpd9nLHR9Is8hfw-Nw8pcbG0j_Zg.Jq_NtZhswBGgW2ne_K1VeA0WF6BPIGblk_0tGj5XmM1xmK_OlVTCNZJBeQ~43ea66669d8d9430e52c1bf328f6dc93
28/05 Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target MT
07/01 UBS Initiates Aligos Therapeutics at Buy With $20 Price Target MT
19/24/19 HC Wainwright Initiates Aligos Therapeutics at Buy With $75 Price Target MT
17/23/17 Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating MT
06/23/06 Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2 MT
06/23/06 Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50 MT
03/22/03 SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating MT
08/22/08 Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11 MT
05/22/05 SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to $3 From $7 MT
23/22/23 Jefferies Lowers Price Target for Aligos Therapeutics to $2.50 From $5, Maintains Hold Rating MT
23/22/23 SVB Leerink Adjusts Aligos Therapeutics' Price Target to $7 from $11, Keeps Outperform Rating MT
23/22/23 Piper Sandler Cuts Aligos Therapeutics to Neutral From Overweight, Price Target to $4 From $15 MT
11/22/11 SVB Leerink Adjusts Aligos Therapeutics' Price Target to $11 from $10, Keeps Outperform Rating MT
16/22/16 SVB Leerink Adjusts Aligos Therapeutics' Price Target to $10 from $15, Maintains Outperform Rating MT
08/22/08 Jefferies Downgrades Aligos Therapeutics to Hold From Buy, Adjusts Price Target to $5 From $20 MT
08/22/08 SVB Leerink Adjusts Aligos Therapeutics' Price Target to $15 from $29, Keeps Outperform Rating MT
07/22/07 JPMorgan Lowers Aligos Therapeutics to Neutral From Overweight, Price Target to $12 From $30 MT
09/21/09 Aligos Therapeutics : SVB Leerink Starts Aligos Therapeutics at Outperform with $29 Price Target MT
17/21/17 Aligos Therapeutics : Piper Sandler Initiates Coverage on Aligos Therapeutics With Overweight Rating, $47 Price Target MT
24/21/24 Aligos Therapeutics : Piper Sandler Adjusts Price Target on Aligos Therapeutics to $40 From $35, Maintains Overweight Rating MT
21/20/21 Aligos Therapeutics : Jefferies & Co Adjusts Aligos Therapeutics PT to $30 From $26, Maintains Buy Rating MT
10/20/10 Aligos Therapeutics : Cantor Fitzgerald Starts Aligos Therapeutics at Overweight With $28 Price Target MT
10/20/10 Aligos Therapeutics : Piper Sandler Starts Aligos Therapeutics at Overweight With $35 Price Target MT
10/20/10 Aligos Therapeutics : JPMorgan Starts Aligos Therapeutics at Overweight With $33 Price Target MT
10/20/10 Aligos Therapeutics : Jefferies & Co Initiates Coverage on Aligos Therapeutics With Buy Rating, $26 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+873.51%
+13.99%
+24.38%
+19.43%
+29.48%
+11.87%
+19.5%
+46.79%
+0.6%
+21.55%
Average +106.11%
Weighted average by Cap. +20.33%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.380USD
Average target price
52.38USD
Spread / Average Target
+873.51%
High Price Target
175.00USD
Spread / Highest target
+3,152.79%
Low Price Target
20.00USD
Spread / Lowest Target
+271.75%

Analyst Consensus Detail

Analyst consensus - Aligos Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Aligos Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Aligos Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALGS Stock
  4. Consensus Aligos Therapeutics, Inc.